When dealing with osteoarthritis, there are many treatment options that patients can consider taking in order to manage their symptoms. Arcoxia is one option. This drug belongs to a group of medicines ...

Merck today withdrew its application with the Food and Drug Administration for Arcoxia, its next-generation painkiller. Many analysts had been expecting the drug to help Merck win a long-standing duel ...

Merck's new pain reliever drug Arcoxia, which was proposed as a successor to Vioxx, was rejected by a federal health advisory panel. The news came out just after the market closed. Merck shares fell ...

A Food & Drug Administration advisory panel last week recommended that Arcoxia, Merck's successor to the recalled Vioxx, not be approved for sale in the U.S. In a vote of 20 to 1, the panel said they ...

The FDA gave painkiller Arcoxia, Merck's successor to Vioxx, the thumbs down today. The decision was expected, given the 20-1 vote against the drug by a committee of experts earlier this month. But ...

Merck & Co. Inc.’s painkiller Arcoxia offers a “marginal” advantage in gastrointestinal safety but seems “worse than” other pain drugs in terms of deaths and serious cardiovascular problems, U.S.

Simply sign up to the US & Canadian companies myFT Digest -- delivered directly to your inbox. Merck suffered a bitter loss on Thursday as a US regulatory panel recommended that its long-studied ...

TRENTON, N.J. — The Food and Drug Administration rejected Merck & Co.’s request to market a successor to its withdrawn arthritis drug Vioxx in the U.S., the drug maker said Friday. The decision was ...

As predicted, US regulators have issued Merck & Co with a non-approvable letter for its painkiller Arcoxia as a treatment for osteoarthritis. As predicted, US regulators have issued Merck & Co with a ...

Merck has released data indicating that Arcoxia performed better than the generic diclofenac in treating arthritis. The data suggests that Arcoxia was no more dangerous than the older drug diclofenac ...

Washington DC - An FDA memo shows that there are concerns over an increase in cardiovascular risk with 2 new COX-2 selective inhibitors that are awaiting approval in the US—etoricoxib (Arcoxia, Merck ...